Tuesday, March 31, 2026

Policy

Policy•Fierce Biotech•Mar 31, 2026

AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan

background ▾

• •AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan

→ Read original article

Policy•Fierce Pharma•Mar 31, 2026

Novo Nordisk cuts 400 roles at troubled Bloomington site

background ▾

• •Novo Nordisk cuts 400 roles at troubled Bloomington site

→ Read original article

Policy•Fierce Biotech•Mar 31, 2026

Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy

background ▾

• •Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy

→ Read original article

Policy•Fierce Biotech•Mar 31, 2026

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play

background ▾

• •Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play

→ Read original article

Policy•Fierce Pharma•Apr 1, 2026

FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen's Tavneos

background ▾

• •FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen's Tavneos

→ Read original article

Market Access

No articles for this category on this date.

Clinical Trials

No articles for this category on this date.